RA'ANANA, Israel, March 18,
2024 /PRNewswire/ -- Inspira™ Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or
"Inspira"), a breakthrough medical technology company, is
excited to announce the AMAR submission for approval of the
INSPIRA™ ART100, marking a significant milestone in Inspira's
venture into new markets.
AMAR - the Israeli Ministry of Health's medical device
regulation unit, is the authority responsible for controlling
medical device licenses and approvals including the issuance of
certificates of free sale which are necessary for marketing
regulatory approvals in the Southeast
Asia and South American markets, potentially propelling the
Company towards targeting exceptional growth opportunities.
"We are immensely proud to submit our initial blood oxygenation
device, the INSPIRA™ ART100 for AMAR approval, ahead of our
INSPIRA™ ART (Gen 2) device designed to treat patients while awake
without the need for mechanical ventilation, marking a pivotal
moment in our mission to redefine life support on a global scale,"
said Dagi Ben-Noon, CEO of Inspira Technologies. "The
enthusiastic support from local key-opinion leaders highlights the
excitement surrounding our technology, setting the stage for its
global journey. Our team has blended advanced engineering,
technology, and design to push the boundaries."
The INSPIRA™ ART (Gen 2) utilizes adaptive blood oxygenation
technology to continuously measure the patient's blood parameters
in real-time to deliver needed oxygen volume straight into the
blood. The unique technology is designed to allow for the targeted
control of oxygenation levels, thereby adapting to the individual
needs of each patient. This method is expected to significantly
reduce complications associated with traditional ventilation
methods, shorten hospital stays and potentially save lives.
The INSPIRA™ ART (Gen 2) device is the culmination of extensive
research and development efforts by the team at Inspira. It is
designed to offer an alternative to traditional mechanical
ventilation, providing patients with a less invasive, more
comfortable, and potentially more effective treatment option. The
device is intended to integrate cutting-edge technologies to
enhance oxygenation, reduce the need for intubation, and improve
overall patient outcomes.
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology
company in the respiratory treatment arena. The Company has
developed a breakthrough Augmented Respiration Technology (INSPIRA
ART), designed to rebalance patient oxygen saturation levels. This
technology potentially allows patients to remain awake during
treatment while reducing the need for highly invasive, risky, and
costly mechanical ventilation systems that require intubation and
medically induced coma. The Company's products have not yet been
tested or used in humans and has not been approved by any
regulatory entity.
For more information, please visit our corporate
website: https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the potential
marketing of its products in the Southeast Asia and South American markets,
that approval by AMAR might propel the Company towards targeting
exceptional growth opportunities, its prospective INSPIRA™ ART (Gen
2) device, and the benefits of the Company's products and potential
products. These forward-looking statements and their implications
are based solely on the current expectations of the Company's
management and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. Except as otherwise
required by law, the Company undertakes no obligation to publicly
release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting the Company is
contained under the heading "Risk Factors" in the Company's annual
report on Form 20-F for the fiscal year ended December 31, 2022 filed with the U.S. Securities
and Exchange Commission (the "SEC"), which is available on the
SEC's website, www.sec.gov
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-announces-amar-regulatory-submission-of-the-inspira-art100-to-enter-the-southeast-asia-and-south-american-markets-302091392.html
SOURCE Inspira Technologies